DeepMed Research

Epizyme, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2007-01-01

Employees: 250

Market Cap: -

Website: http://www.epizyme.com

Clinical Trials

Tazemetostat Expanded Access Program for Adults With Solid Tumors

Conditions: Epithelioid Sarcoma (Ex-US Only)
Spindle Cell Sarcoma
Sinonasal Carcinoma
Small Cell Carcinoma of the Ovary Hypercalcemic Type
Thoracic Sarcoma
Poorly Differentiated Chordoma
ATRT
Malignant Rhabdoid Tumor of Kidney
Malignant Rhabdoid Tumor of Ovary
Malignant Rhabdoid Tumor

First Posted Date: 2019-03-14

Last Posted Date: 2024-03-22

Lead Sponsor: Epizyme, Inc.

Registration Number: NCT03874455

Epithelioid Sarcoma Natural History Study

Completed

Conditions: Epithelioid Sarcoma

First Posted Date: 2019-02-12

Last Posted Date: 2024-03-07

Lead Sponsor: Epizyme, Inc.

Target Recruit Count: 74

Registration Number: NCT03837678

Locations: 🇺🇸
University of Colorado Cancer Center, Denver, Colorado, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 2 locations

Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients

Phase 1

Completed

Conditions: Diffuse Large B Cell Lymphoma
Primary Mediastinal Lymphoma
Mantle Cell Lymphoma
Advanced Solid Tumor
Marginal Zone Lymphoma

Interventions: Drug: Tazemetostat
Drug: Fluconazole
Drug: Omeprazole
Drug: Repaglinide

First Posted Date: 2017-01-23

Last Posted Date: 2023-06-26

Lead Sponsor: Epizyme, Inc.

Target Recruit Count: 32

Registration Number: NCT03028103

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors

Phase 1

Completed

Conditions: Primary Mediastinal Lymphoma
Mantle-Cell Lymphoma
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Marginal Zone Lymphoma
Advanced Solid Tumors

Interventions: Drug: Tazemetostat and [14C] Tazemetostat

First Posted Date: 2017-01-05

Last Posted Date: 2024-03-22

Lead Sponsor: Epizyme, Inc.

Target Recruit Count: 3

Registration Number: NCT03010982

Locations: 🇬🇧
The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom
🇬🇧
Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, United Kingdom

A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study

Phase 1

Active, not recruiting

Conditions: Mesothelioma
Renal Medullary Carcinoma
Non-Hodgkin Lymphoma (NHL)
Follicular Lymphoma (FL)
Synovial Sarcoma
Diffuse Large B-cell Lymphoma (DLBCL)
Epitheliod Sarcoma (ES)
Advanced Solid Tumors

Interventions: Drug: Tazemetostat

First Posted Date: 2016-08-23

Last Posted Date: 2025-05-01

Lead Sponsor: Epizyme, Inc.

Target Recruit Count: 58

Registration Number: NCT02875548

Locations: 🇺🇸
Hematology Oncology Associates of the Treasure Coast - Port St. Lucie, Port Saint Lucie, Florida, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

and more 31 locations

Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma

Phase 2

Completed

Conditions: Mesothelioma
BAP1 Loss of Function

Interventions: Drug: Tazemetostat

First Posted Date: 2016-08-09

Last Posted Date: 2021-04-09

Lead Sponsor: Epizyme, Inc.

Target Recruit Count: 74

Registration Number: NCT02860286

Locations: 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
City of Hope National Medical Center, Los Angeles, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 13 locations

EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Phase 1

Completed

Conditions: INI1-negative Tumors
Synovial Sarcoma
Malignant Rhabdoid Tumor of Ovary
Rhabdoid Tumors

Interventions: Drug: Tazemetostat

First Posted Date: 2015-11-11

Last Posted Date: 2024-10-03

Lead Sponsor: Epizyme, Inc.

Target Recruit Count: 109

Registration Number: NCT02601937

Locations: 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Texas Children's Cancer and Hematology Center, Houston, Texas, United States

and more 32 locations

A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Malignant Rhabdoid Tumors (MRT)
Rhabdoid Tumors of the Kidney (RTK)
Synovial Sarcoma
INI1-negative Tumors
Malignant Rhabdoid Tumor of Ovary
Renal Medullary Carcinoma
Epithelioid Sarcoma
Atypical Teratoid Rhabdoid Tumors (ATRT)
Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval)
Any Solid Tumor With an EZH2 GOF Mutation

Interventions: Drug: Tazemetostat

First Posted Date: 2015-11-11

Last Posted Date: 2025-03-11

Lead Sponsor: Epizyme, Inc.

Target Recruit Count: 267

Registration Number: NCT02601950

Locations: 🇫🇷
Institut Curie, Paris, France
🇧🇪
University Hospital Leuven, Leuven, Belgium
🇫🇷
Centre Leon Berard, Lyon, France

and more 29 locations

A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Acute Lymphocytic Leukemia
Acute Leukemias
Leukemia

Interventions: Drug: EPZ-5676

First Posted Date: 2014-05-20

Last Posted Date: 2023-06-18

Lead Sponsor: Epizyme, Inc.

Target Recruit Count: 18

Registration Number: NCT02141828

Locations: 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Emory Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

and more 6 locations

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

Phase 1

Completed

Conditions: B-cell Lymphomas (Phase 1)
Advanced Solid Tumors (Phase 1)
Diffuse Large B-cell Lymphoma (Phase 2)
Follicular Lymphoma (Phase 2)
Transformed Follicular Lymphoma
Primary Mediastinal Large B-Cell Lymphoma

Interventions: Drug: Tazemetostat
Drug: Prednisolone

First Posted Date: 2013-07-12

Last Posted Date: 2024-03-26

Lead Sponsor: Epizyme, Inc.

Target Recruit Count: 400

Registration Number: NCT01897571

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy